Dr. E. J. Bow
 
Sections of Infectious Diseases and Haematology/Oncology
Professor and Head , Section of Haematology/Oncology
Department of Internal Medicine, University of Manitoba ;
Head , Department of Medical Oncology and Haematology,
Director , Infection Control Services, CancerCare Manitoba .

Degrees: M.D. (U Calgary, 1976), MSc. (McMaster, 1975), D. Bacteriol. (U Toronto, 1972), FRCPC (1980)

Mailing Address: ON-2081, CancerCare Manitoba, 675 McDermot Avenuet , Winnipeg , MB, R3E 0V9.

Tel: (204) 787-3964, Fax: (204) 786-0196
E-mail: eric.bow@cancercare.mb.ca

Research Interests:
The prevention and management of bacterial and fungal infections in neutropenic cancer patients, the impact of cytotoxic therapy-induced intestinal epithelial damage on the pathogenesis of invasive infection in cancer patients; and the impact of cytotoxic therapy upon quality of life in cancer patients. .

Recent Publications:

For an up to date link to publications from Dr. Bow please click here

Book Chapters

  1. Bow E.J., Chapter 5: Infectious complications in patients receiving cytotoxic therapy for acute leukemia: History, background, and approaches to management. In: Infections in Acute Leukemia Wingard J.R., Anaissie E.J. (eds), Martin Dunitz Ltd., London, U.K. 2003: 71-104.
  2. Bow E.J. : Assessment of Risk by Invasive Fungal Infection among Oncology Patients. In: Fungal Infection in Immunocompromised Patients . Wingard J.R., Anaissie E.J. (eds). 2004 (in press)
  3. Rosser SJ, and Bow EJ. Infections in Neutropenic Hosts. In: Evidence-Based Infectious Diseases . Loeb M, Smieja M, Smaill F. (eds), BMJ Publishing Group, London, UK. 2004: 241-256.
  4. Bow EJ. Chapter 47: Approach To Infection In Patients Receiving Cytotoxic Chemotherapy for Malignancy. In: Principles of Critical Care Hall JB, Schmidt GA, Wood LDH (eds), McGraw-Hill Inc., New York, 3rd Edition, 2005: 735-770.
  5. Bow EJ. Chapter 4: Assessment of the Risk for Invasive Fungal Infection Among Oncology Patients. In: Fungal Infections in the Immunocompromised Patient . Wingard JR, Anaissie EJ (eds). Boca Raton , FL : Taylor & Francis Group, 2005: 97-128.
  6. Gingerich J, Bow EJ . Approach to the Complications of Treatment for Acute Leukemia in the Elderly. In: Seminars in Hematology: Acute Leukemia in the Elderly . Estey EH (eds), 2006: 43(2): 134-143.

Publications in Refereed Journals

  1. Doucette K.E., Galbraith P.A., Bow E.J. , Binda B.J., Rendina A., Embil J.M. Disseminated zygomycosis: a rare cause of infection in patients with hematologic malignancies. J Trauma. 2003; 55(3): 568-70.
  2. Ellison , C.A. , Natuik , S.A. , Fischer, J.M.M., McIntosh, A.R., Scully, S.A., Bow, E.J., Danilenko, D.M., Hayglass, K.T., Gartner, J.G. Effect of recombinant human keratinocyte growth factor (rHuKGF) on the immunopathogenesis of intestinal graft-vs.-host disease induced without a preconditioning regimen. J Clin Immunol. 2004; 24(2) 197-211.
  3. Bow EJ . Point: Fluoroquinolone-Based Antibacterial Chemoprophylaxis in Neutropenic Cancer Patients Works for Defined Outcomes in Defined Populations, But Must be Used Wisely. JNCCN 2004; 2(5)433-444.
  4. Harding GAJ, Bow EJ . Commentary. Infectious Complications of Lung Cancer. Oncology 2005;19(2):195-99.
  5. Bow EJ . Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients. Medical Mycology 2005: (43) Suppl 1: S277-S287.
  6. Bow EJ . Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clin Microbiol Infect. 2005: (11) Suppl 5:24 -29.
  7. Bow EJ , Rotstein C, Noskin GA, Laverdière M, Schwarer AP, Segal BH, Seymour JF, Szer J, Sanche S. A Randomized, Open-Label, Multi-Center Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam and Cefepime for the Empiric Treatment of Febrile Neutropenic Episodes in Patients with Hematologic Malignancies. Clin Infect Dis. 2006; update 43(4): 447-59.
  8. Za rychanski R, Wlodarczyk K, Ariano R, Bow EJ . Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate. J Antimicrob Chemoth 2006; 58:228-30.
  9. Bow EJ , Meddings JB. Intestinal Mucosal Dysfunction and Infection during Remission-induction Therapy in Acute Myeloid Leukemia. Leukemia 2006; 20(12): 2087-92.
  10. Bow EJ. Considerations in the Approach to Invasive Fungal Infections in Patients with Haematological Malignancies. Br J Haematol 2008; 140(2): 133-52.
Abstracts
  1. Fatoye, A., Bow, E.J., Loewen, R.: Amphotericin B Lipid Complex (ABLC) and Caspofungin as combination therapy for disseminated Fusariosis in a patient with acute myeloid leukemia (AML). ISHAM, Abstract #392, San Antonio , Texas , May 25-29, 2003 .
  2. Bow, E.J., Schwarer, A.P., Laverdière, M., Segal, B.H., Anaissie, E.: Efficacy of Piperacillin/Tazobactam as Initial Empiric Therapy of Febrile Neutropenia in Patients with Haematological Malignancy. 43 rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract #3778, Chicago , Illinois , September 14-17, 2003 .
  3. Bow, E.J., Noskin, G.A., Schwarer, A.P., Laverdière, M., Vesole, D.H. Efficacy of piperacillin/Tazobactam as Initial Empiric Therapy of Febrile Neutropenia in Patients with Hematologic Malignancy. Blood 2003; 102 (11) Abstract #1000, p. 281a.
  4. Gartner, J.G., Ellison, C.A., Natuik, S.A., Fischer, J.M.M., Bow, E.J., Scully, S.A. Recombinant Human Keratinocyte rowth Factor (rHuKGF) Exacerbates Renal Pathology in a Murine Model of Chronic Graft-vs-Host Disease (GVHD). ASH, Abstract #3539, San Diego , California , December 8, 2003 . . Blood 2003; 102 (11) Abstract #3539, p. 950a.
  5. Benke S, Bow EJ , Schacter B, Loughery J, Benjaminson P, Seftel MD, Rubinger M. Infectious Morbidity and Hospitalization Requirements of Patients with Acute Myeloid Leukemia Receiving Intensive Outpatient Consolidation. Blood 2004; 104(11) Abstract #4524, p 214b.
  6. Dao V, Rubinger M, Bow EJ , Schacter BA, Shore TB, Woloschuk D, Demers A, Sun X, Seftel MD. Epidemiology of Adult Acute Lymphoblastic Leukemia in Manitoba , Canada : Does This Approximate Clinical Trial Data? Blood 2005: 106(11) Abstract #4554, p 217b.